ABVC BioPharma, Inc.

Equities

ABVC

US00091F3047

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.7941 ^USD	-7.45%		-15.07%	-31.54%

May. 09	Abvc Biopharma, Inc. Enters into A Definitive Agreement with Oncox Biopharma, Inc	CI
Apr. 10	ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	CI

ABVC BioPharma, Inc. Announces Executive Changes

June 15, 2023 at 05:00 pm EDT

ABVC BioPharma, Inc. announced that Dr. Richard King, the Company's Chief Scientific Officer of the company, notified the Company of his resignation, effective June 13, 2023. The Company's board of directors appointed Dr. Tsung-Shann (T.S.) Jiang to replace Dr. King as the Company's CSO. Dr. Jiang currently serves as the Company's Chief Strategy Officer and is one of the Company's directors.

Latest news about ABVC BioPharma, Inc.

Abvc Biopharma, Inc. Enters into A Definitive Agreement with Oncox Biopharma, Inc	May. 09	CI
ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	Apr. 10	CI
ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation	Mar. 26	CI
ABVC BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
ABVC BioPharma Signs Licensing Deal With Senior Paradise	Feb. 15	MT
ABVC BioPharma, Inc. Executes a Definitive Agreement to Receive License Fees of $3 Million and Royalties of 2% on Future Revenue	Feb. 15	CI
ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC	Jan. 16	CI
Top Premarket Decliners	Jan. 04	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	Jan. 03	MT
Sector Update: Health Care	Jan. 03	MT
Traders Anticipate Fed Minutes as US Equity Futures Decline Pre-Bell	Jan. 03	MT
Top Midday Gainers	Jan. 03	MT
ABVC BioPharma, Inc. Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study	Dec. 07	CI
ABVC BioPharma, Inc. announced that it expects to receive $1 million in funding from The Lind Partners, LLC	Nov. 16	CI
ABVC BioPharma, Inc. Enters Definitive Agreement with Licensing Income Worth $467 Million and Royalties Up to $200 Million	Nov. 16	CI
Earnings Flash (ABVC) ABVC BIOPHARMA Reports Q3 Revenue $15,884	Nov. 15	MT
ABVC BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
Wall Street Set to Open Lower as GDP, Jobless Claims Higher Than Expected	23-10-26	MT
ABVC BioPharma Enters Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million	23-10-26	CI
Abvc Biopharma, Inc. Announces Completion of Subject Recruitment for Interim Analysis on Adhd Phase Iib Clinical Study	23-10-17	CI
Top Premarket Gainers	23-09-15	MT
ABVC BioPharma, Inc. announces tranche update	23-08-23	CI
ABVC BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
ABVC BioPharma, Inc. Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration	23-08-03	CI
Top Midday Gainers	23-08-01	MT

Chart ABVC BioPharma, Inc.

Duration

Period

More charts

Company Profile

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.

Sector

Biotechnology & Medical Research

Calendar

2024-11-10 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.7941

Average target price

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABVC BIOPHARMA, INC.	-31.54%	8.36M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs